Contact Us
Chengguan District, Lanzhou, Gansu, China
© 2025 Jeifer Pharmaceutical, All Right
Reserved.
Chemists started tinkering with acrylic acids back in the 1930s, driven by a hunt for new materials that would challenge the old standards set by natural gums or cellulose. Wartime shortages pushed industries to think beyond the familiar, and researchers landed on polyacrylic acid (PAA) as a tool for binding, thickening, and gelling. Wartime improvisation turned into peacetime innovation, and drug makers realized this resin could improve controlled release medicines or stabilize suspensions. Over the decades, governments, including Britain and the USA, began cementing standards to govern the purity and performance of this polymer, giving rise to specific grades in the British Pharmacopoeia (BP), European Pharmacopoeia (EP), and United States Pharmacopeia (USP). That shift from laboratory oddity to pharmaceutical essential didn’t happen overnight. It took a generation of chemists, doctors, and regulators learning by trial and error what best serves both science and public health.
Polyacrylic acid resin IV for pharmaceutical use takes the form of a white, powdery polymer. This grade delivers consistent thickening and mucoadhesive behavior. If you’ve struggled with liquid suspensions that separate or ointments that run, this resin delivers an easy win for product stability. It’s not just about better consistency, either. In tablets, the resin gives precise control over drug release rates—those tiny changes in timing can mean the difference between a once-daily pill and a three-times-a-day hassle. Notably, pharmaceutical grades like this leave out most contaminants and monomer residues common in industrial resins. Think less about chemical factories and more about clean, closely monitored labs.
A bag of polyacrylic acid resin IV looks like white, fluffy snow, but don’t let its appearance fool you. This polymer chain, built from many acrylic acid molecules, absorbs huge quantities of water, swelling into a gel-like structure. Its high molecular weight usually sits well above 450,000, creating thick, slow-moving solutions. In the lab, the resin dissolves in water, yielding mildly acidic, viscous mixtures with pH values that can swing between 2.5 and 7, depending how it’s neutralized. The backbone is loaded with carboxyl groups, giving the polymer its unique mucoadhesive and ion-exchanging qualities. Physical structure holds up to pharmaceutical scrutiny, with specified particle size, solubility, and moisture levels.
Pharma-grade resins get a full diagnostic workup before ever entering a manufacturing line. Each batch undergoes testing for molecular weight (commonly by gel permeation chromatography), viscosity (using precise rotational viscometers), and residual monomer content down to parts per million. Inspectors look hard at heavy metals, microbiological load, and ash content. Labels must spell out grade, batch number, storage recommendations, and legal marks matching BP, EP, or USP requirements. Any manufacturer failing these checks won’t keep contracts for long. If you care about real-world safety, you care about these labels and specs—there’s no shortcut around quality.
Making pharmaceutical-grade polyacrylic acid resin starts with free-radical polymerization, a process where acrylic acid monomers link up in the presence of initiators, often peroxides or redox pairs. Factories control temperature, initiator levels, and pH through tightly monitored reactors, avoiding wild swings that invite unwanted side reactions. After the reaction wraps, the product undergoes extensive washing and drying to remove residual monomers and byproducts—a multi-step routine that sets pharmaceutical resins apart from cheaper industrial grades. This step-by-step cleaning means fewer irritants and greater safety down the medicine line.
With its reactive carboxyl groups, this resin isn’t a static ingredient. Manufacturers can neutralize the acid using sodium or calcium ions, fine-tuning its swelling and solubility. Cross-linking—tying polymer chains together with agents like divinyl glycol—transforms a loose water-absorber into a robust hydrogel that won’t wash away easily. Researchers graft other polymers or active molecules onto polyacrylic acid’s backbone, creating derivatives for specific drug release profiles, improved mucoadhesion, or targeted delivery. Through these modifications, the resin adapts to the toughest assignment, whether binding aspirin in a tablet or delivering chemotherapy agents to a specific organ.
This resin wears a lot of names, adding some confusion for buyers and pharmacists alike. Most folks in the industry know it as polyacrylic acid resin. The marketplace also sees ‘Carbomer’, ‘Carbopol’, or specific codes like ‘Carbomer 940’. Regulatory documents might reference it by its CAS number 9003-01-4. Commercial catalogues add more trade names every year, but pharmacy shelves still rely on its main aliases. No matter the label, the job stays the same: thicken, bind, protect, or release medicine as required.
It’s too easy to overlook how much safety engineering goes into each shipment of pharmaceutical-grade polyacrylic acid. Factories operate under GMP (Good Manufacturing Practices) guidelines, tracking everything from raw material sourcing to filter integrity in packing rooms. Workers wear protective clothing, and routine air and surface tests ensure no contamination creeps in. On the user’s end, pharmacopoeia monographs spell out test procedures for limits on residual solvents, heavy metals, and microbe counts. The standard operating procedures aren’t about checking boxes; they keep patients safe, batch after batch.
Pharmaceutical manufacturers reach for this resin for one big reason: reliability in tablet and topical drug delivery. In tablets, it acts as a controlled-release matrix—those extended-release painkillers that spare you constant dosing rely on a polymer just like this. Topical creams count on the resin’s gelling power to spread evenly and stay put. Suspensions and oral liquids gain from the way the resin suspends actives without separating. Dentistry uses it to anchor adhesives and gels. Hospital pharmacies, compounding specialists, and branded drug giants all lean on the resin’s ability to do the job right, every time.
Innovators never stop testing new ways to make polyacrylic acid resin work harder. Research groups experiment with new cross-linking agents to create smarter hydrogels that respond to changes in pH or temperature, pushing the boundaries of site-specific drug delivery. Some labs focus on mixing polyacrylic acid with biodegradable polymers to create safer carriers for sensitive actives. Pilot lines experiment with particle engineering for faster dissolving or smoother mouthfeel. Every round of research sends another question back to the start: can we get better patient outcomes by tailoring our polymer strategy?
Medical chemists and toxicologists have run polyacrylic acid resin through animal models and cell cultures to draw the line on safe exposure. Typical findings support its reputation as a low-toxicity pharmaceutical polymer. In acute studies, the resin rarely causes harm, provided monomer residues stay within guideline limits. Long-term exposures showed little accumulation or immunological disruption. Regulators still watch for hypersensitivity reactions, especially with high-dosage topical applications. Overexposure risks focus mainly on impurities—contaminants, heavy metals, volatile organics—not the pure resin itself. Patient safety arguments depend on rigorous manufacturing controls and constant batch verification.
The coming years look promising for polyacrylic acid resin IV, mainly because drug delivery keeps evolving. Rising demand for once-daily pills, personalized medicine, and biosimilar formulations challenge ingredient suppliers to deliver ever-purer, more customizable polymers. Research points toward “smart” derivatives—hydrogels tuned to unique triggers, or drug carriers that release only at target sites. Environmental and regulatory pressures may drive the move to greener synthesis routes or biodegradable versions, trimming down the environmental cost of mass pharmaceuticals. If anything, the next decade promises more work for chemists, more stringent standards for manufacturers, and, most of all, sharper focus on what really matters—safe, effective treatments built on ingredients that people can trust.
In tablet making, consistency can make or break a product. Polyacrylic acid resin doesn’t just keep everything together—it delivers a predictable structure that folks in pharma aim for. I remember sitting in a lab as a new chemist, realizing how a tough binder can solve flaky blends. Polyacrylic acid resin pulls those ingredients into a solid, tough tablet that can handle shipping and tossing, without crumbling apart.
You won’t often find a medicine shelf without something that’s been held together with this compound. It shows up in over-the-counter painkillers and complex, multi-layer formulas. It’s flexible enough to work with different active ingredients, and its safety profile lines up with strict pharmacopoeial standards of BP, EP, and USP. Keeping that high safety bar protects both the patient and the brand.
Anyone who has taken a pill wants it to do its job at the right time and place. Polyacrylic acid resin controls how fast a tablet falls apart or dissolves. This isn't just about convenience—sometimes a slow-release is exactly what doctors want. Cholesterol medicines use it to keep drug levels even, instead of delivering everything at once. That means fewer side effects and more predictable results.
My former colleagues used to talk about "buffering the storm" in medicines. Polyacrylic acid resin helps coat drugs, feeding them out as the body digests. You’re less likely to get a rush of medicine too fast, and more likely to get steady benefit. Pediatric and geriatric meds rely on that controlled breakdown to protect sensitive stomachs or create chewable tablets that kids won’t spit out.
Not every medicine comes as a solid. Syrups and suspensions use polyacrylic acid resin to thicken liquids, preventing heavy ingredients from sinking or clumping. This can be just as crucial as any fancy active molecule—nobody wants grit at the bottom of a cough syrup. The resin gives a smooth feel and steady flow, so dosing stays accurate.
Pharmacists get fewer complaints about “lumpy” or separated liquids thanks to this resin. The material swells on contact with water and holds onto enough moisture to keep suspensions stable, even on pharmacy shelves that see dozens of temperature swings daily.
Safety means more than just avoiding toxins. Polyacrylic acid resin helps by creating protective barriers in certain drug forms. It shields delicate drugs from stomach acid, breaking down only once the pill passes into the intestine. In drugs like some antibiotics or anti-inflammatories, this step stops stomach upset and lets the active ingredient work exactly where doctors want.
Many industry experts keep pushing for greener, less wasteful manufacturing. Polyacrylic acid resin—when used well—cuts down on the need for extra stabilizers or preservatives. Going forward, I see a real push toward reusing water and cutting solvent waste in facilities that work with this resin. Supply chains, too, get streamlined: fewer ingredients, fewer headaches about purity or cross-contamination.
Pharma needs tools that handle real-world demands. Polyacrylic acid resin stands out for its safety, its muscle in holding things together, and its role in delivering medicine responsibly. As health standards grow tougher, using compounds that have been studied and trusted across so many countries keeps patients safer and supply chains simpler. That’s what keeps me convinced of its place on the formulary shelf.
Pharmaceuticals often include ingredients that sound technical. Polyacrylic acid resin IV, marked BP, EP, USP, signals that it meets some strict standards—British Pharmacopoeia, European Pharmacopoeia, and United States Pharmacopeia. These standards exist for a reason. Regulators don't certify a compound without pouring over its safety data and manufacturing process. In my experience reading regulatory documents, these benchmarks matter, because drug quality and patient well-being stand on that foundation.
Drug makers favor polyacrylic acid resins for things like taste-masking and controlled-release tablets. These resins don’t just hold a pill together; they can influence how medicine behaves in the stomach. Quality in pharma goes beyond the gloss of GMP certificates and pharma-grade labels. Every batch needs to be as pure as the last, with no slip-ups in the recipe.
Researchers have checked out polyacrylic acid resins for decades. Test after test in animal models focused on what happens after it’s swallowed—does it irritate, does it get absorbed, does it spark allergies? Results show that, in the tiny doses used, the body ignores most of it. It slides through and gets flushed out. Doctors don’t rely on luck, though. Every excipient must show it won’t cause harm over the long haul.
I’ve met pharmacists and quality control experts who stress that USP, BP, and EP grades are not a marketing trick. These standards put a ceiling on contaminants. If there’s too much acrylic acid monomer left, or traces of metals sneak in, the batch fails. Regulatory agencies—think FDA or EMA—demand this paperwork every single year. Patients often don’t realize that any pharma-grade ingredient must clear hurdles for heavy metals, microbial contamination, and residue solvents. Companies run molecular fingerprinting and trace analysis with gear that can find a contaminant smaller than a grain of sand.
Transparency gives me some peace. Pharmaceutical companies must show their sourcing, testing, and batch tracking if an inspector turns up. The audit trail allows independent labs to check if the polyacrylic acid resin in one batch matches what regulators approved. If anyone finds a problem, recall procedures shut down sales, and authorities post warnings. I’ve seen how public transparency pushes companies to keep bad batches away from shelves.
A few questions linger about chronic exposure and environmental load. Polyacrylic acid resins, on a chemical level, don’t break down in nature as fast as sugar or protein. Researchers keep studying whether trace amounts in waste streams collect in animals or soil. Balancing drug quality against environmental health takes real scientific effort and isn’t solved by a certificate alone.
For now, people can trust that pharmaceutical-grade polyacrylic acid resin, checked under the rules of BP, EP, and USP, stays at a solid safety level for medicine. Industry, regulators, and academics must keep watching, reporting problems, and improving. That’s the only path to build and hold public trust in the drug supply chain.
Polyacrylic acid resin, at Pharma grade, goes straight into some of the most sensitive products in the world—pharmaceuticals. This resin stabilizes, thickens, and acts as a binder. Its role in drug formulation is overlooked until something goes wrong. In my years working close to pharmaceutical supply chains, I’ve seen how a lapse in the basics—such as storage or handling—can turn a safe ingredient into a safety risk.
The chemistry of polyacrylic acid resin means it absorbs water from the air. Let a bag sit open on a humid dock floor, and before long, the contents start clumping or losing their intended properties. Very low moisture environments suit this resin. Warehouses should stick close to 25°C (77°F) and keep the humidity low, often no higher than 50%. Before policies or procedures, a reliable dehumidifying system makes the biggest difference. I once walked through a facility where the storage controls had failed. The resin had absorbed so much moisture that it wouldn’t blend smoothly in formulation, and QA flagged half the batch for incineration.
This resin breaks down under strong UV light. Sunlight filtering through warehouse windows will slowly damage its molecular structure. The best facilities place sensitive ingredients—like polyacrylic acid resin—in dark containers, away from direct light. Opaque, sealed drums work best, and everyone who handles the resin needs a reminder: Always reseal immediately. Exposure to the air cheats not just the product's performance but also patient safety.
Leaving polyacrylic acid resin in its original, airtight packaging remains a stubborn but true best practice. Manufacturers design the packaging to guard against water, light, dust, and contamination. Repackaging in substandard bags or containers introduces risks of cross-contact with other powders—something auditors and regulators look for. Any time I see resin decanted into generic bins, I remember the recall triggered by simple mishandling. Shelves should be clean, nothing stacked too high, and bags never rest on the floor where spills go unnoticed.
This resin does not forgive shortcuts. Tools—scoops, spatulas, trays—should show no trace of residue from previous jobs. Even tiny amounts of detergent, another powder, or cleaner can spark an investigation or spoil a batch. Gloves and masks serve more than just staff protection; they keep the resin clear of skin oils and microbes. Facilities that drill staff on these points face fewer audits, and product quality stays high.
Polyacrylic acid resin reacts to its environment, not just in storage but also in transit. During shipping, heat and jostling can compromise the integrity of packaging. The safest carriers use insulated trucks during hot months, monitor interior conditions, and document any temperature outliers during long journeys. Delays that expose resin to heat or forklift traffic raise compliance flags and can cost time in quarantine checks.
Neglect in any of these areas tends to show up in lost batches, regulatory fines, or even drug recalls. Every step in the chain—storage conditions, handling discipline, protection from contamination or air—plays into the overall safety and function of the finished pharma product. With health on the line, these basics cannot stay just on paper. They must guide actions every day, in every facility, rain or shine.
Polyacrylic Acid Resin IV has a routine yet critical job in medicines, especially in forming coatings, controlled-release matrices, and drug delivery systems. Having worked in a pharmaceutical R&D lab, I can vouch that excipients aren’t just extra ingredients. The backbone of how a tablet performs, tastes, and dissolves depends on the properties and reliability of these resins. Polyacrylic acid’s crosslinked structure helps mediate how a pill swells, releases its load, and resists wear in transit and storage.
Pharmaceutical specification for Polyacrylic Acid Resin IV follows strict criteria under pharmacopeias like BP (British Pharmacopoeia), EP (European Pharmacopoeia), and USP (United States Pharmacopeia). It isn’t about ticking boxes; the safety and consistency of every batch of medicine ride on these points.
Molecular Weight:Resin IV falls in a sweet spot—its average molecular weight usually hits 450,000 to 1,800,000 Daltons. Polymer chains in this range support thickening, gel formation, and sustained release. Labs use size-exclusion chromatography to confirm this range, sidestepping issues like unexpected tablet breakdown or gritty mouthfeel.
Appearance:Pharma resins must appear as fine, white, odorless powders. Simple as it seems, impurities show up as beige or off-white tones. I remember once rejecting a whole consignment for a slight color shift—no cutting corners when patient safety is involved.
Identity and Assay:FTIR or NMR spectroscopy confirm material identity, while titration or UV-VIS spectrophotometry determines purity. Usually, the resin tests above 99% purity on a dried basis, with assay values not drifting below 98.5%. Deviations might hint at unreacted acids or foreign polymers.
Residue on Ignition:A key indicator of inorganic contamination, this test demands less than 0.1% residue. High values signal failure points like leftover catalysts or additive carryover, both red flags in tablet manufacturing.
Monomers and Impurities:Unreacted acrylic acid monomer content sticks below 0.25 ppm. Higher monomer traces may cause toxicity or allergic reactions. Strict limits on heavy metals, often under 10 ppm (lead, arsenic, mercury), reduce risks of bioaccumulation in patients who take chronic meds.
Loss on Drying:This value, typically under 2.0%, reflects moisture content. Extra water skews dosing and wrecks batch stability. My team spent hours in humidity-controlled labs, drying small batches to get this parameter just right before sending samples to Quality Assurance.
pH Range:Suspensions made from the resin in demineralized water need to maintain pH between 2.5 and 3.5. If acids or bases slip through during production, the pH drifts, increasing the risk of unwanted reactions in compounded medicines.
Drug product recalls often trace back to failed excipient quality. Polyacrylic acid resin manufacturers carry the burden of traceability, lot-to-lot reproducibility, and transparent documentation. Modern production plants use high-pressure reactors, and every finished bag passes analytical screens before release. Auditors look for GMP (Good Manufacturing Practice) marks, ISO certifications, and digital batch records, so every step meets published pharmacopeial specs—and regulators don’t go easy on infractions.
Most successful pharmaceutical companies work closely with resin suppliers. On-site visits, supplier quality agreements, and periodic audits help spot risks early. Developing a solid risk assessment plan for incoming raw materials shortens response time if something ever goes wrong. Technicians and quality managers rely on detailed Certificates of Analysis, and advanced analytics like LC-MS catch outliers quickly. For innovators in pharma, partnering only with compliant, reputable sources is as much about peace of mind as regulatory paperwork.
Pharmaceutical technologists see Polyacrylic Acid Resin Iv BP EP USP used across a wide range of oral dosage forms. It isn’t just another ingredient—how you select the concentration and blend it plays a big role in how well a product performs. In immediate-release tablets, for instance, formulators lean on lower concentrations—often less than 1%—to help tablet integrity and mouthfeel. Move into sustained-release or matrix-type tablets, and the needed levels climb, sometimes to 2% or over, to guarantee proper gelling and drug release rates.
You can’t just sprinkle it in and hope for the best. I’ve sat at benches where one batch works and another falls apart, simply because a shift in mixing order caused clumping or uneven wetting. This polymer wants precise handling. If it’s added straight to water too quickly, giant lumps form and ruin a batch. Slow, even sprinkling under fast agitation sorts this out. It sounds simple until you’re the one with a sticky beaker and wasted time.
Modified-release tablets use this resin to control how a drug enters the body. Here the amount depends on testing. Each drug brings different solubility and stability challenges. Usually, you run through a series of trials—small changes, careful dissolution testing after each batch. Sometimes, a mere 0.5% shift changes everything. In my experience, for high-viscosity grades, hitting that perfect spot between too stiff and too loose can mean days of test runs.
Let’s talk about patient safety. Too much resin slows breakdown and delays release—potential for underdosing or side effects. Too little, and you end up with dose dumping. Stock formulas only go so far. What matters is careful testing and close attention to what each API brings to the table.
Guidelines from the pharmacopeias aren’t just boxes to tick—they help shape safe practice. These texts expect you to explain your process: why that grade, why that ratio, what happens during stability. I’ve seen inspection findings take down promising development projects, all because someone skipped a dissolution profile or relied on a supplier’s numbers instead of their own lab data.
Then come impurities and toxicology. Some resins aren’t engineered for human use. Quality matters more than marketing—auditable proof of grade, traceability, and testing for acrylic acid content stay high on my checklist. If a resin supplier can’t hand over a Certificate of Analysis covering BP, EP, or USP standards, I move on.
Tablets aren’t the only concern. Liquid suspensions, topical gels, and coatings draw on the same foundation of knowledge. Each application changes how the resin is wetted, neutralized, and blended. In liquids, it takes slow pH adjustment and steady stirring to avoid runaway viscosity spikes or precipitation. Gels need careful balancing—too heavy a hand with neutralizer, and you move from silk to sludge.
Real stories from the lab say it all. One cough syrup project nearly failed because Formula B used a local water supply with inconsistent hardness, which threw the carbomer dispersion into chaos. Only after tracking the source did the viscosity stabilize batch after batch. That’s not isolated—those details define success.
It’s easy to assume one guideline fits all, but formulation work tells another story. Working with polyacrylic acid resin asks for patience, trial by error, and respect for the compound’s quirks. Care for your batch setup, validate every process change, and make data your foundation. These steps honor both the science and those who trust the medications we make.
| Names | |
| Preferred IUPAC name | poly(1-carboxyethylene) |
| Other names |
Carbomer Carbopol Poly(acrylic acid) PAA Acrylic acid polymer |
| Pronunciation | /ˌpɒli.əˈkrɪ.lɪk ˈæsɪd ˈrɛzɪn aɪ viː biː piː juː ɛs piː ˈfɑːmə ɡreɪd/ |
| Identifiers | |
| CAS Number | 9003-01-4 |
| Beilstein Reference | 14763 |
| ChEBI | CHEBI:53411 |
| ChEMBL | CHEMBL1201478 |
| ChemSpider | 58103 |
| DrugBank | DB09465 |
| ECHA InfoCard | ECHA InfoCard: 100.013.748 |
| EC Number | 9003-01-4 |
| Gmelin Reference | 20901 |
| KEGG | C13557 |
| MeSH | Dental Materials"[MeSH] |
| PubChem CID | 31145 |
| RTECS number | UN0390000 |
| UNII | 7S0W1F7U98 |
| UN number | UN3077 |
| Properties | |
| Chemical formula | (C3H4O2)n |
| Molar mass | 72.06 g/mol |
| Appearance | White or almost white, hygroscopic, powder or granules |
| Odor | Odorless |
| Density | 1.22 g/cm³ |
| Solubility in water | Soluble in water |
| log P | log P: -1.02 |
| Acidity (pKa) | 4.5-5.0 |
| Basicity (pKb) | 11.5 |
| Refractive index (nD) | 1.48 |
| Viscosity | 400 to 900 mPa.s |
| Dipole moment | 1.74 D |
| Pharmacology | |
| ATC code | A01AB11 |
| Hazards | |
| Main hazards | Causes eye irritation. Causes skin irritation. May cause respiratory irritation. |
| GHS labelling | GHS02, GHS07 |
| Pictograms | GHS07, GHS08, GHS05 |
| Signal word | Warning |
| Hazard statements | No hazard statements. |
| Precautionary statements | P264, P280, P305+P351+P338, P337+P313 |
| NFPA 704 (fire diamond) | 2-1-0 |
| Lethal dose or concentration | LD₅₀ Oral - rat - > 2,000 mg/kg |
| LD50 (median dose) | > 6400 mg/kg (Rat, Oral) |
| PEL (Permissible) | 10 mg/m³ (as particulates, nuisance dust) |
| REL (Recommended) | Not more than 5 mg/kg body weight |
| IDLH (Immediate danger) | Not established |
| Related compounds | |
| Related compounds |
Polyacrylamide Polymethacrylic acid Polyvinyl alcohol Polyethylene glycol Carbomer Sodium polyacrylate |
Chengguan District, Lanzhou, Gansu, China
